Summary
This research project aims to understand how platelet integrin αIIbβ3 is kept inactive in circulating platelets and how its activity is regulated in health and disease, utilizing novel synthetic ligand-mimetic compounds.
Platelet alphaIIbbeta3 activation and its therapeutic targeting
US · IL
NIH
grant
awarded
#nih-2R01HL141366-05A1
What they want
The project will investigate the mechanisms by which platelet integrin αIIbβ3 remains inactive in free-flowing platelets despite the presence of its ligand fibrinogen. It will also define the activation state of the integrin during the formation of the contracting platelet-fibrin meshwork in clot retraction, leveraging previously developed pure antagonists. The goal is to provide a more complete understanding of αIIbβ3 regulation and insights into clot retraction.
Technical requirements
- Cryo-electron microscopy (cryo-EM) for structural determination of full-length αIIbβ3
- Development and utilization of synthetic ligand-mimetic compounds (pure antagonists)
